ProNAi To Present Phase II Clinical Data For New Cancer DrugProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells' DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
Esperion Gets Positive Results From New Study Of Cholesterol DrugEsperion Therapeutics Inc. Friday announced "positive" results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.
AlphaCore Pharma Starts Clinical Trial Of New Heart DrugThe biopharmaceutical company AlphaCore Pharma Friday announced it had started a Phase 1 study of its drug candidate, ACP-501, for the treatment of high-risk atherosclerosis and serious lipid metabolism disorders.
Adeona Gets Results From Alzheimer's Product CandidateAnn Arbor-based Adeona Pharmaceuticals Inc. late Thursday reported top-line results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease and mild cognitive impairment.
Wayne State Conducts Research Study For Fibroids